Open Collections

Description

Therapeutics Letter 76 reviews the harms and benefits of selective serotonin reuptake inhibitors (SSRIs) in pregnancy. Conclusions and clinical implications: There is no evidence that SSRIs in pregnancy improve maternal or infant health, and substantive evidence that they pose a risk to the fetus. Thus the harms exceed the benefits in this setting. Non-drug options such as cognitive behavioural therapy or psychotherapy are also unproven, but do not carry a risk to the fetus. The common argument of their lack of availability is not relevant for this relatively small, high priority population. If a patient wants to stop SSRIs in pregnancy, it is best to taper the dose over at least 1 week to minimize withdrawal symptoms. Exercise, social support, sleep hygiene and good nutrition are important for all pregnant people, including those with symptoms of depression.